Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 102, October 2018, Pages 40-48

A.G.J. van Rossum, M. Kok, E. van Werkhoven, M. Opdam, I.A.M. Mandjes, A.E. van Leeuwen - Stok, H. van Tinteren, A.L.T. Imholz, J.E.A. Portielje, M.M.E.M. Bos, A. van Bochove, J. Wesseling, E.J. Rutgers, S.C. Linn, H.M. Oosterkamp,